Trial reportJournal of thrombosis and thrombolysis2006
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Trial report in Journal of thrombosis and thrombolysis, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease.Systematic reviews · 2014Pooled it
- Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis.Caspian journal of internal medicine · 2020Review
- Antiplatelet Therapy in Acute Coronary Syndrome.European cardiology · 2017Review
- Circulating primers enhance platelet function and induce resistance to antiplatelet therapy.Journal of thrombosis and haemostasis : JTH · 2015Article
- Evaluation of Aggregometery Parameters and Efficacy of Plavix versus Clopidex in Patients Suffering from Ischemic Heart Disease: A Randomized Double Blind Clinical Trial.Iranian Red Crescent medical journal · 2014Article
- Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.British journal of clinical pharmacology · 2011Review
- Old and new molecular mechanisms associated with platelet resistance to antithrombotics.Pharmaceutical research · 2010Review
- Clinical importance of aspirin and clopidogrel resistance.World journal of cardiology · 2010Article
- Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.Journal of thrombosis and thrombolysis · 2010Article
- Antiplatelet Resistance-Does it Exist and How to Measure it?Clinical medicine. Cardiology · 2009Article
- Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements.Nature reviews. Cardiology · 2009Review
- Aspirin resistance.Advances in hematology · 2009Article
- Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.Journal of translational medicine · 2008Article
- Aspirin resistance in atherosclerosis.Current atherosclerosis reports · 2008Review
- Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain.Journal of thrombosis and thrombolysis · 2008Article
- A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes.Journal of thrombosis and thrombolysis · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease.
aimThe aim of our study was to determine; the prevalence of aspirin resistance in patients with acute coronary syndromes, the role of aspirin resistance on outcome in the follow-up and the effect of clopidogrel therapy in the prevention of MACE in aspirin resistant subjects. MATERIAL AND
methodsWe detected the prevelance of aspirin resistance in 105 patients with acute coronary syndrome. Platelet functions were analyzed in Platelet Function Analyzer (PFA)-100 (Dade Behring, Germany) with collagen and/or epinephrine (Col/Epi) and collagen and/or ADP (Col/ADP) cartridges. Primary end points of the study were myocardial infarction, unstable angina, cardiac death.
results19% (n = 20) of patients were aspirin resistant by PFA-100. In the follow-up, MACE occured in 9 patients (45%) with aspirin resistance and in 10 patients (11.7%) with aspirin sensitive platelet aggregation (p = 0.001). Multivariate analysis showed that aspirin resistance was an independant predictor of MACE. The prevalence of MACE in patients who were on clopidogrel treatment for 12 months were lower compared to those who were on a clopidogrel treatment for the first six months (p = 0.040).
conclusionsWe determined that the MACE risk in patients with acute coronary syndromes having detected aspirin resistance, was higher at statistically significant levels compared to patients having aspirin sensitive platelet aggregation. Our results showed that aspirin resistance, was an independant predictor of MACE in patients with acute coronary syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.